Possible Beneficial Effect of Telmisartan on Glycemic Control in Diabetic Subjects
- Sachiko Honjo, MD1,
- Yuichi Nichi, MD12,
- Yoshiharu Wada, MD1,
- Yoshiyuki Hamamoto, MD, PHD1 and
- Hiroyuki Koshiyama, MD, PHD12
- 1Center for Diabetes and Endocrinology, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
- 2Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto, Japan
- Address correspondence to Hiroyuki Koshiyama, MD, PhD, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan. E-mail: h-koshiyama{at}kitano-hp.or.jp
In a recent issue of Diabetes Care, Pershadsingh and Kurtz (1) reported an interesting case subject with impaired glucose tolerance, whose insulin resistance and triglycerides improved on the angiotensin II type 1 receptor blocker telmisartan. Telmisartan has a unique agonist activity of the peroxisome proliferator–activated receptor γ (PPARγ) in vitro (2). It reduces glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet (2). These results suggest that telmisartan may have a beneficial effect on glycemic control in type 2 diabetes.
We investigated the effect of …
